← Back to Clinical Trials
Recruiting NCT06096532

NCT06096532 Adipose Tissue Blood Flow in Aging Humans

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06096532
Status Recruiting
Phase
Sponsor Mayo Clinic
Condition Healthy
Study Type INTERVENTIONAL
Enrollment 24 participants
Start Date 2024-02-15
Primary Completion 2028-12-30

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 80 Years
Study Type INTERVENTIONAL
All Conditions
Interventions
75 gm oral glucose load

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 24 participants in total. It began in 2024-02-15 with a primary completion date of 2028-12-30.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The goal of this basic science clinical trial is to understand whether adipose tissue blood flow changes between younger and older healthy adults. The main question\[s\] it aims to answer are: * Is basal and nutrient responsive adipose tissue blood flow (ATBF) different between younger and older adults * What molecular and systemic signatures related to adipose tissue blood flow are altered between these two groups. Participants will undergo measurements of adipose tissue blood flow using the xenon washout technique, undergo 2 abdominal subcutaneous adipose tissue biopsies, and drink a sugary drink.

Eligibility Criteria

Inclusion criteria * Within the ages of 18-35 years or 65-80 years at time of study visit * BMI between 20-25.0 kg/m2. Exclusion criteria: * Presence of diagnosed cardiometabolic diseases (e.g., Type 2 diabetes, hypertension, Heart Failure) * Taking prescription anticoagulants * Taking prescriptions or supplements that effect adipose tissue metabolism (i.e., statins, Thiazolidinediones, niacin, atypical antipsychotics, or fish oil) * Pregnant or nursing * Inability to provide written informed consent * Smokers

Contact & Investigator

Principal Investigator

Kelli Lytle, PhD

PRINCIPAL INVESTIGATOR

Mayo Clinic

Frequently Asked Questions

Who can join the NCT06096532 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying Healthy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06096532 currently recruiting?

Yes, NCT06096532 is actively recruiting participants. Visit ClinicalTrials.gov or contact Mayo Clinic to inquire about joining.

Where is the NCT06096532 trial being conducted?

This trial is being conducted at Rochester, United States.

Who is sponsoring the NCT06096532 clinical trial?

NCT06096532 is sponsored by Mayo Clinic. The principal investigator is Kelli Lytle, PhD at Mayo Clinic. The trial plans to enroll 24 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology